U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Sulopenem etzadroxil and probenecid – Oral Products
  1. Development Resources

Sulopenem etzadroxil and probenecid – Oral Products

 

Minimum Inhibitory Concentrations
(mcg/mL)

Disk Diffusion
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteralesa

≤ 0.25

0.5

≥ 1.0

≥ 19

16-18

≤ 15

S = susceptible; I = intermediate; R = resistant

a Clinical efficacy was shown for E. coli, K. pneumoniae, and P. mirabilis.

Back to Top